HK1254030A1 - 治療自身免疫病症和同種免疫病症的方法 - Google Patents

治療自身免疫病症和同種免疫病症的方法

Info

Publication number
HK1254030A1
HK1254030A1 HK18112887.1A HK18112887A HK1254030A1 HK 1254030 A1 HK1254030 A1 HK 1254030A1 HK 18112887 A HK18112887 A HK 18112887A HK 1254030 A1 HK1254030 A1 HK 1254030A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating autoimmune
alloimmune disorders
alloimmune
disorders
Prior art date
Application number
HK18112887.1A
Other languages
English (en)
Inventor
格雷漢姆‧帕里
帕維爾‧A‧尼基廷
桑迪普‧帕尼克
Original Assignee
比奧貝拉蒂美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比奧貝拉蒂美國公司 filed Critical 比奧貝拉蒂美國公司
Publication of HK1254030A1 publication Critical patent/HK1254030A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18112887.1A 2015-06-26 2018-10-10 治療自身免疫病症和同種免疫病症的方法 HK1254030A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
HK1254030A1 true HK1254030A1 (zh) 2019-07-12

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112887.1A HK1254030A1 (zh) 2015-06-26 2018-10-10 治療自身免疫病症和同種免疫病症的方法

Country Status (13)

Country Link
US (2) US20180169240A1 (zh)
EP (1) EP3313417A4 (zh)
JP (1) JP6963509B2 (zh)
KR (1) KR20180020296A (zh)
CN (1) CN108348600A (zh)
AU (2) AU2016282782A1 (zh)
BR (1) BR112017027578A2 (zh)
CA (1) CA2990662A1 (zh)
EA (1) EA038567B1 (zh)
HK (1) HK1254030A1 (zh)
IL (1) IL256424B1 (zh)
MX (2) MX2017016835A (zh)
WO (1) WO2016210172A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889170C (en) 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
MX2018013222A (es) 2016-04-29 2019-04-22 Pfizer Anticuerpos de interferon beta y usos de los mismos.
US20240092889A1 (en) * 2019-10-16 2024-03-21 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
US20040115194A1 (en) * 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
JP5739326B2 (ja) * 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
RU2012102021A (ru) * 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
CA2889170C (en) * 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) * 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene

Also Published As

Publication number Publication date
IL256424A (en) 2018-02-28
EP3313417A1 (en) 2018-05-02
BR112017027578A2 (pt) 2018-08-28
CN108348600A (zh) 2018-07-31
MX2023002021A (es) 2023-03-15
MX2017016835A (es) 2018-08-01
JP6963509B2 (ja) 2021-11-10
CA2990662A1 (en) 2016-12-29
AU2022215307A1 (en) 2022-09-08
EA201890106A1 (ru) 2018-05-31
IL256424B1 (en) 2024-05-01
AU2016282782A1 (en) 2018-01-18
EP3313417A4 (en) 2019-06-12
JP2018526330A (ja) 2018-09-13
KR20180020296A (ko) 2018-02-27
EA038567B1 (ru) 2021-09-15
WO2016210172A1 (en) 2016-12-29
US20220249664A1 (en) 2022-08-11
US20180169240A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
IL285151A (en) Methods for the treatment of fgf21-related disorders
HK1251455A1 (zh) 聚糖治療劑和治療方法
HRP20210526T8 (hr) Oksisteroli i postupci za njihovu uporabu
IL289976A (en) Oxysterols and methods of using them
HK1255500A1 (zh) 氧固醇及其使用方法
HK1254030A1 (zh) 治療自身免疫病症和同種免疫病症的方法
HK1259294A1 (zh) 用於治療自身免疫疾病和癌症的組合物及方法
IL282482A (en) Variants of protoxin-II and methods of use
IL259861A (en) Methods and preparations for the treatment of disorders related to seizures
IL282508A (en) Variants of protoxin-II and methods of use
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
IL265568A (en) Methods for treating TIM-3 elevation
PL3654965T3 (pl) Sposoby leczenia autoimmunologicznych chorób mikronaczyniowych
GB201503371D0 (en) Methods of screening and treatment
GB201522615D0 (en) Methods of screening and treatment
GB201505437D0 (en) Methods of screening and treatment
GB201503392D0 (en) Methods of screening and treatment
GB201421511D0 (en) Methods of screening and treatment